WO2006047183A2 - Recombinant dna nicking endonuclease and uses thereof - Google Patents

Recombinant dna nicking endonuclease and uses thereof Download PDF

Info

Publication number
WO2006047183A2
WO2006047183A2 PCT/US2005/037607 US2005037607W WO2006047183A2 WO 2006047183 A2 WO2006047183 A2 WO 2006047183A2 US 2005037607 W US2005037607 W US 2005037607W WO 2006047183 A2 WO2006047183 A2 WO 2006047183A2
Authority
WO
WIPO (PCT)
Prior art keywords
dna
cvipii
nicking endonuclease
seq
protein
Prior art date
Application number
PCT/US2005/037607
Other languages
French (fr)
Other versions
WO2006047183A3 (en
Inventor
Shuang-Yong Xu
Zhenyu Zhu
Shi-Hong Chan
Yan Xu
Original Assignee
New England Biolabs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Biolabs, Inc. filed Critical New England Biolabs, Inc.
Priority to US11/666,148 priority Critical patent/US20080268507A1/en
Publication of WO2006047183A2 publication Critical patent/WO2006047183A2/en
Publication of WO2006047183A3 publication Critical patent/WO2006047183A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)

Definitions

  • DNA nicking endonucleases cleave one strand of DNA in a sequence-specific and strand-specific manner. Although there are over 240 type II restriction endonucleases with unique specificities isolated from bacterial and viral sources, only a few site-specific nicking endonucleases are currently commercially available (Roberts et al. Nucl. Acids Res.
  • nicking endonucleases consist of either genetic engineering from existing restriction endonucleases or screening from bacterial and viral sources.
  • the nicking endonuclease N.BstNBI and N.BstSEI (5' GAGTCN 4 A 3') were found in strains of Bacillus stearothermophilus (Morgan et al. Biol. Chem. 381 : 1123-1125 (2000); Abdurashitov et al. MoI. Biol.
  • an isolated DNA segment encodes a protein with DNA cleavage activity where the protein has an amino acid sequence that has at least about 25% amino acid sequence identity with SEQ ID NO:29.
  • the protein is capable of cleaving, at a specific site, a single DNA strand in a duplex where the specific cleavage site is for example, CCA, CCG or CCT.
  • the isolated DNA segment may be further characterized as having a DNA sequence with at least about 40% DNA sequence identity with SEQ ID NO:28.
  • the isolated DNA segment encodes a protein with DNA cleavage activity where the DNA segment has at least about 10 contiguous bases identical to sequences contained in SEQ ID NO:28.
  • a protein of this type is capable of cleaving, at a specific site, a single
  • DNA strand in a duplex where the specific cleavage site is for example, CCA, CCG or CCT.
  • the isolated DNA segment encodes a protein with DNA methylase activity, which shares at least about 47% amino acid sequence identity with SEQ ID NO:31.
  • the sequence of the DNA segment shares at least about 53% DNA sequence identity with SEQ ID NO:30.
  • a recombinant nicking endonuclease is provided that has an amino acid sequence sharing at least about 25% sequence identity with SEQ ID NO:29 and a recombinant DNA methylase, is provided which shares at least about 47% amino acid sequence identity with
  • a recombinant nicking endonuclease wherein the endonuclease is a mutant having a deletion at the C-terminal end.
  • mutants with deletions of about 51 and 19 amino acid residues at the C-terminus end retain their specificity for CCA, CCG and CCT.
  • a vector in an embodiment of the invention, includes a segment of DNA, which has a sequence that has at least about 10 contiguous bases identical to sequences contained in SEQ ID NO:28.
  • a host cell containing this vector is also provided.
  • a method for amplification of DNA that includes the steps of incubating the DNA with a DNA polymerase capable of strand displacement and a recombinant nicking endonuclease (as described above) and obtaining amplified DNA.
  • This amplification method can be performed isothermally.
  • An additional amplification step may optionally be added to the method in which random primers and a strand displacement polymerase are added to the amplified DNA to enhance the yield of the amplification by another round of amplification.
  • polymerases for use in the method include Bst polymerase, Thermomicrobium roseum pol I and E. coli DNA polymerase large (Klenow) fragment.
  • An example of the recombinant nicking endonuclease is Nt.CviPII.
  • the DNA may be obtained from a single bacterial colony.
  • a method for eliminating DNA from a sample of biological material that includes (a) adding Nt.CviPII nicking endonuclease or mutant thereof to the sample of biological material; and (b) allowing the nicking endonuclease or mutant thereof to cleave the DNA so as to eliminate the DNA from the sample of biological material.
  • a method for cloning a toxic nicking endonuclease depends on removing a C-terminal sequence from the DNA encoding the toxic nicking endonuclease; and cloning the truncated gene in a suitable host cell such as E. coli.
  • This approach has worked effectively for toxic enzymes cloned from Chlorella viruses.
  • Figure IA shows a cartoon of the CviPII nicking- modification system.
  • This system contains 2332 nucleotides and two complete open reading frames (ORFs).
  • the methyltransferase contains 8 motifs typically found in m5C DNA methyltransferases but lacks motif IX and X that are also typical of methyltransferases from organisms other than chlorella.
  • the nicking endonuclease has two active site motifs that are characteristic of some restriction endonucleases.
  • Figure IB shows a small amount of Nt.CviPII purified from E. coli analyzed by SDS-PAGE using 4-10% gel.
  • Lane 1 is Nt.CviPII while lane 2 is a molecular weight marker.
  • Figure 2A shows an alignment of the M.CviPII sequence (SEQ ID No I) with another chlorella methyltransferase (M.CviPI) sequence (SEQ ID. No. 2) and a bacterial methyltransferase (M.Hhal) sequence (SEQ. ID. No 3).
  • Motifs I through X of m5C methyltransferase are marked. conserveed residues in the motifs are indicated by dots. Sequences that are identical are shown in black boxes.
  • Figure 2B shows the amino acid sequences for Nt.CviPII
  • Figure 3A shows the results of the experiment that probes the putative M-CviPII methylation site.
  • the DNA is p ⁇ JC-cviPIIM expressing M-CviPII.
  • the DNA was isolated and digested with Mspl or ScrFI.
  • the first cytosine at the Nt-CviPII cleavage site of CCD was shown to be methylated because the plasmid was cleaved by ScrFI but was resistant to Mspl digestion.
  • Figure 3B is a chromatogram showing target sequences for methylation by M-CviPII.
  • PCR products derived from sodium bisulfide-treated p ⁇ JC-cviPIIM are compared to those from un-treated p ⁇ JC-cviPIIM.
  • the change of cytosine to thymidine corresponds to unmodified cytosine, whereas the presence of cytosine in both sodium bisulfide-treated and un ⁇ treated DNA indicates C 5 -methylcytosine.
  • Results for recognition sites CCT, CCG (SEQ ID NOS:8 and 9), CCA (SEQ ID NOS: 10 and 11), CCCG (SEQ ID NOS: 12 and 13) show that the first Cs are methylated in CCN triplets.
  • the result for CCAA (SEQ ID. No. 14 and 15) show relaxed specificity towards the second C of CCAA.
  • the modified nucleotides are indicated by down arrows.
  • Figure 4A compares the results from IPTG-induced Nt.CviPII expression and un-induced cell extract under a lac promoter on pUC19 DNA.
  • Supernatant of the lysate of induced (upper panel) and un-induced culture (lower panel) from equivalent cultures were loaded on a SP FF column and eluted with linear gradient of 0.1-1 M NaCI.
  • High DNA nicking activity was obtained with IPTG induction.
  • Figure 4B shows that Nt.CviPII is surprisingly thermostable being active at least to temperatures of 6OC.
  • 0.5 ⁇ g of pUC19 was incubated with 1 unit of Nt.CviPII for 1 hour at various temperatures (lanes 2-10). The reactions were stopped and analyzed by electrophoresis on 1.5% agarose gel.
  • Lane 11 is linearized pUC19 DNA
  • lane 12 is supercoiled pUC19 DNA
  • lanes 1 and 13 are 100 base pair size markers.
  • Figure 4C shows the results of Nt.CviPII-cleaved pUC19 and single stranded M 13 phage DNA by electrophoresis on 6% poly-acrylamide gel with 7 M urea. Lane 1 : size marker.
  • Lane 2 pUC19 (double strand DNA) with 1 unit of Nt.CviPII.
  • Lane 3 M13 (single strand DNA) with 1 unit of
  • Lane 4 M 13 (single strand DNA) with 0.5 units of Nt.CviPII.
  • Lane 5 M 13 (single strand DNA) with 0 units of Nt.CviPII.
  • Lane 6 LMW: low molecular weight DNA size marker.
  • Figure 5 shows that CCA and CCG are the preferred substrates (SEQ ID NOS: 18 and 19) for Nt-CviPII cleavage.
  • Nt.CviPII does not cleave at CCC but instead cleaves at the overlapping CCA site (SEQ ID NO:20).
  • CCT shows low-level cleavage by Nt-CviPII (SEQ ID NO: 21).
  • TGG corresponds to CCA
  • CGG to CCG CGG
  • GGG to CCC GGG to CCC
  • AGG to CCT Triplet sequences in boxes are CCN sites designed on the substrate DNA.
  • Native CCA sequences of pUC19 are underlined.
  • the arrowheads indicate the cleavage site.
  • the arrows under the chromatographs and the bracketed "a" in the schematic indicate the adenine added by the template-independent activity of Taq DNA polymerase used in sequencing reactions at the cleavage site.
  • Figure 6 shows a schematic outline of isothermal amplification using Nt.CviPII and Bst DNA polymerase I large fragment.
  • Figure 7A shows that nicking-endonuclease mediated isothermal amplification of DNA prefers a DNA polymerase with strand displacement activity.
  • Purified E. coli DNA was incubated with Nt.CviPII in combination with Bst DNA polymerase I large fragment (Bst), T. roseum (Tro), Vent DNA polymerase, T. aquaticus (Taq) or E. coli DNA polymerase I
  • FIG. 7B shows the results of isothermal amplification of purified DNA from T. thermophilus and ⁇ phage.
  • T. thermophil ⁇ s and ⁇ DNAs were amplified with Nt.CviPII and Bst DNA polymerase I large fragment. The amplified products were analyzed by 1.5% agarose gel electrophoresis.
  • Lanes 2 and 4 shows the results of amplification only in the presence of both enzymes.
  • Lane 5 is a marker.
  • Lanes 1 and 3 show results from an amplification reacton containing only Bst DNA polymerase I large fragment and no Nt.CviPII. No detectable
  • Figure 7C shows that on 10-20% polyacrylamide gel with 7 M urea, the amplified DNA from Figure 7B are resolved into single-stranded DNA from ⁇ 25 to over 500 nt.
  • Figure 7D shows that DNA can be amplified from a single bacterial colony subjected to heat treatment to release the DNA. Only a fraction of DNA was amplified without heating the cells (lane 6).
  • Lane 1 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment, CviPI and Nt.CviPII.
  • Lane 2 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment
  • Lane 3 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment only.
  • Lane 4 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment, Mspl and Nt.CviPII.
  • Lane 5 is Bst DNA polymerase I large fragment, and Nt.CviPII with no DNA template.
  • Lane 6 is the non-heat treated cells from a single colony incubated with Bst DNA polymerase I large fragment, and Nt.CviPII.
  • Figure 8 shows DNA nicking activity of two Nt.CviPII truncation mutants.
  • Four-fold dilutions of NPN297 or NPN329 (1 unit, 0.25 units, 0.06 units and 0.02 units) were incubated with 1 ⁇ g of pUC19 DNA at 37 0 C for 1 hour.
  • the cleavage products were analyzed on a 1.5% agarose gel in TBE.
  • Supercoiled (SC) and linearized (L) pUC19 DNA and a marker were included for comparison.
  • Figure 9 shows the results of Nt.CviPII truncation mutant-mediated DNA amplification.
  • NPN297 (0.25 units) was used in combination with Bst DNA polymerase I large fragment (2 units) in the presence of 0.2 mM dNTPs and designated amount of ⁇ DNA. The reactions were carried out at 55°C for 30 minutes.
  • FIG. 10 shows the efficient removal of genomic DNA by
  • Lane M 2-log DNA ladder (New England Biolabs, Inc., Ipswich, MA).
  • Lane 1 reverse transcription (RT) without M-MuLV reverse transcriptase
  • Lanes 2 and 4 RT with M-MuLV reverse transcriptase
  • Lane 3 RT without M-MuLV reverse transcriptase, but in the presence of 0.5 unit of Nt.CviPII;
  • Lane 5 RT without M-MuLV reverse transcriptase, but in the presence of 2 units of Nt.CviPII.
  • Figure HA shows the DNA sequence of the CviPINt. gene (SEQ ID NO:28).
  • Figure HB shows the amino acid sequence of the CviPIINt. gene (SEQ ID NO:29).
  • Figure 12A shows the DNA sequence of the CviPIIM gene (SEQ ID NO:30).
  • Figure 12B shows the amino acid sequence of the CviPIIM gene (SEQ ID NO:31).
  • the nicking endonuclease Nt.CviPII described here has been cloned from a chlorella virus referred to as NYs-I.
  • the CviPII nicking and modification system was cloned and expressed in E. coli. Initially, the cviPIIM gene was cloned in
  • E. coli by the methyltransferase selection method.
  • the adjacent ORFs were sequenced directly from the viral DNA.
  • a downstream ORF showed some amino acid sequence identity to a restriction endodnuclease CviJI (RG ⁇ CY) in a BlastP search of all known genes in GeneBank.
  • Nt.CviPII Nt.CviPII fused to an intein and chitin-binding domain
  • the combination of truncation and fusion decreased the toxicity of the nicking endonuclease to the host cells so that the fusion protein was over-expressed in E. coli strain ER2566 (New England Biolabs, Inc., Ipswich, MA).
  • the fusion proteins were purified by chitin column chromatography and the fusion part was removed by self- cleavage activity of the intein induced by reducing agent.
  • Nt.CviPII truncation mutants were further purified by standard chromatographic steps.
  • the truncation mutants of Nt.CviPII were found to possess the same sequence specificity but lower specific activity than the wild-type enzyme.
  • Nt.CviPII Due to the high frequency of Nt.CviPII cleavage sites and its partial duplex cleavage product, Nt.CviPII was used in conjunction with several DNA polymerases in isothermal random DNA amplification. An assay system was developed to determine conditions for isothermal amplification. This assay system is described in Example 3. Using this approach, it is possible to show amplification of a DNA using Nt.CviPII and
  • Figure 6 shows that DNA can be amplified from a single bacterial colony.
  • Nt.CviPII may also be used in prior art methods of isothermal amplification that utilize nicking endonucleases. These include: strand displacement amplification, exponential DNA amplification (EXPAR) or nick translation with DNA polymerases such as Klenow fragment, Bst DNA polymerase, Thermomicrobium roseum DNA pol I large fragment, or phi 29
  • DNA can be amplified from a single E. coli colony using Nt.CviPII and a strand displacement DNA polymerase ( Figure 7D).
  • the cells in the single colony have been broken by heat to release DNA but any other method in the art can be used where preferably no additional purification steps are required before performing amplification.
  • DNase I is the most commonly used enzyme in DNA contaminant removal from RNA samples. DNase I is a non ⁇ specific nicking endonuclease that works on single-stranded DNA, double-stranded DNA, and DNA-RNA hybrids. After DNAse I treatment, the enzyme must be removed from the
  • RNA sample before other applications such as RT-PCR.
  • DNase I is heat-resistant and therefore phenol extraction is required to remove DNase I completely (Aguila et al. BMC Molecular Biology 6:9 (2005)).
  • Nt.CviPII is a sequence-specific nicking endonuclease that recognizes double-stranded DNA only. Therefore, the DNA contaminant removal can be done by Nt.CviPII simultaneously with the reverse transcription reaction so that no extra purification steps are required. By choosing a different frequent nicking endonuclease, a different digestion pattern can also be achieved.
  • nicking endonucleases described herein may be used for creating single-stranded regions in duplex nucleic acids. Such single-stranded regions can take the form of gaps interior to the duplex, or terminal single-stranded regions. Single-stranded termini can be crafted to allow linkage of various elements via base-pairing with elements containing a complementary single-stranded region. This joining is useful, for example, in an ordered, oriented assembly of DNA modules to create cloning or expression vectors. This joining is also useful in attaching detection probes and purifying DNA molecules containing the single-stranded region. Gaps are useful in similar applications, including attaching detection or purification probes (U.S. Patent No. 6,660,475 and U.S. Patent Publication No. 2003-0194736 Al herein incorporated by reference).
  • nicking endonucleases described herein can be used to label DNA. At first, nicks are introduced into DNA by
  • DNA polymerases with strand displacement activity can be used to replicate DNA.
  • Radioactive dNTP, biotinylated dNTP, or dNTP with fluorophore modification can be added in the DNA extension reaction.
  • the newly synthesized DNA should be labeled according to the dNTP used.
  • nicking fragment DNA polymorphism can be used to detect gene mutations if the point mutation takes place within the nicking site recognition sequence.
  • nicking endonucleases described herein can be used to prepare relaxed circular DNA under limited nicking conditions, e.g., using diluted Nt.CviPII.
  • DNA is first nicked by Nt.CviPII provided that the plasmid contains at least one CCD site.
  • the supercoiled DNA should be converted to nicked-open circular DNA, which can be gel- purified.
  • the purified nicked DNA is treated with DNA ligase to generate relaxed circular DNA.
  • Chlorella virus NYs-I genomic DNA was digested partially with Sau3AI and ligated to a BamHI-digested and
  • CIP-treated pUCAC (a derivative of pUC19 by inserting a PCR- amplified chloramphenicol resistant gene into AfIIII site of pUC19) and the ligated DNA was used to transform ER1992 competent cells to construct a Sau3AI genomic DNA library. Approximately 10 5 ampicillin resistant transformants were pooled and plasmid DNA was prepared. Clones that expressed M.CviPII methylase were selected by digesting pooled ampicillin and chloramphenicol resistant plasmids with Mspl (cleaves CCGG and C m CGG sequences but not m CCGG sequence). Eighteen plasmids from the Sau3AI genomic library were found to be partially resistant to Mspl digestion. The inserts of six isolates were sequenced, which revealed an identical open reading frame (ORF, 1092 bp) that had 45.2% amino acid (aa) identity to the NYs-I encoded M.CviPI
  • the putative cviPIIM gene was amplified by PCR and ligated into pUC19 at the Sphl and Sail sites and transferred into E. coli ER2502.
  • In vivo activity of M.CviPII was tested by challenging the plasmid isolated from ER2502 [p ⁇ JC-cviPIIM].
  • the plasmid was incubated with Mspl (C A CGG) or ScrFI (CC ⁇ NGG) at 37°C for 1 hour in NEBuffer 2 (10 mM Tris-HCI,
  • the plasmid pUC- cviPIIM used in methylase protection assay was treated with sodium bisulfide (EZ DNA Methylation Kit, Zymo Research
  • the sodium bisulfide-treated DNA was purified by Qiaprep spin-columns (Qiagen, Valencia, CA) and used for PCR using primers that amplified the cviPIIM gene (MP-Sphl-F and MP-SaII-F).
  • Untreated plasmid was also amplified by the same pair of primers as control. Methylated cytosines were protected from sodium bisulfide that converted un-modified cytosines to uracils, which are amplified as thymidines in PCR. Thus, by comparing with control PCR product, cytosine residues that became thymidines were un-modified while those that remained cytosines were methylated. Sequencing of PCR-amplified DNA from the sodium bisulfide-treated pUC-cviPIIM indicated that most of the first but not the second cytosine of CCG, CCA and CCT are modified (Fig. 3B). Surprisingly, the first two cytosines in
  • CCCG and CCAA were also modified (Fig. 3B, Table 2).
  • methylation of the first C in CCCG indicated that M.CviPII also methylates CCC site, a result of relaxed methyltransferase activity.
  • Modification of the first and second Cs in CCAA suggested that M.CviPII modifies cytosine in relaxed recognition sequence under over- expressed condition (the cviPIIM gene was cloned in a high- copy-number plasmid and IPTG-induced).
  • Nt.CviPII Due to the frequent Nt.CviPII nicking sites, difficulties in cloning the cviPHNt gene in E. coli were encountered. Initially, Nt.CviPII was expressed using in vitro transcription and translation system. A low level of nicking activity was detected in the lysate in comparison with the native Nt.CviPII. However, it was difficult to achieve a clear digestion pattern. To achieve sufficient enzyme for purification, the Nt.CviPII system was modified for expression in E. coli. The expression host ER2683 was pre-modified by expression of M.CviPII via introduction of pUC-cviPIIM.
  • the expression strain ER2683 [pUC-cviPIIM, pR976- cviPIINt] was successfully constructed.
  • M.CviPII that was constitutively expressed under the control of lac promoter on pUCAC protected the host DNA from basal expression of the Nt.CviPII.
  • the Nt.CviPII expression plasmid alone could not transform E. coli cells, indicating that the residual expression of Nt.CviPII in the absence of the cognate methyltransferase is lethal to the host.
  • induced or un-induced cultures of the expression strain ER2683 [pUC-cviPIIM, pR976-cviPIINt] were grown and partially purified by anion-exchange chromatography. The fractions were tested for DNA nicking activity.
  • a single colony of ER2683 [pUC-cw ' PIZ ⁇ f, pR976- cviPIINt] was grown to mid-log phase in 2 liters of rich medium (10 g/l Tryptone, 5 g/l yeast extract, 5 g/l NaCI, pH adjusted to 7.2 with NaOH) containing Amp (0.1 mg/ml), kanamycin (Km, 0.05 mg/ml) and tetracycline (Tc, 0.01 mg/ml) at 30 0 C at 280 rpm.
  • One liter of culture was induced with 0.25 mM IPTG and the other was not. Both cultures were incubated at 16°C for 18 hr and cells were harvested by centrifugation.
  • the cell pellets (wet weight of 3.9 g for the induced culture and 5.0 g for the un-induced culture) were sonicated in 100 ml of 20 mM sodium phosphate, 0.1 M NaCI, pH 7.4. After centrifugation, the soluble fractions were loaded on a SP FF (25 ml bed volume, Amersham Biosciences, now GE Healthcare, Uppsala, Sweden) column and eluted with a linear gradient of 0.1-1 M NaCI. Two ⁇ l of the fractions were incubated with 0.5 mg of pUC19 at 37°C for 1 hr. Reactions were stopped by adding 25 mM EDTA and analyzed by agarose gel electrophoresis. DNA nicking activity was distinguished from non-specific host nucleases. Non-specific nucleases produce a smear while Nt.CviPII produces a characteristic banding pattern of the digested DNA.
  • the 300 mM imidazole fraction was concentrated and assayed. All purified protein preparations were concentrated by VIVASPIN 20 (10,000 MWCO, VIVASCIENCE) and stored in 10 mM NaHPO4, 250 mM NaCI, pH 7.0 with 50% glycerol at -2O 0 C.
  • N-terminal sequencing of the purified protein eluted in 50 mM imidazole revealed a MSTPQAKTKYY sequence (SEQ ID NO:6), which corresponds to amino acids 5 to 15 in Nt.CviPII.
  • this fraction contains a protein initiated at the fifth codon of cviPIINt, which is an ATG.
  • Mass spectrometry showed that the mass of this protein is 34, 110 Da, compared to the predicted value of 40,069 Da. This preparation was designated His " -Nt.CviPII.
  • Nt.CviPII activity was measured at 16°C, 20 0 C, 25 0 C, 3O 0 C, 37 0 C, 45°C, 55 0 C, 6O 0 C and 65°C on 0.5 ug of pUC19 substrate in NEBuffer 4 (20 mM Tris-acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 1 mM DTT, pH 7.9, New England Biolabs, Inc., Ipswich, MA) (Fig. 5A). DNA nicking activity was highest at 30-45 0 C, whereas the activity at 20-25 0 C was higher than that at 55-60 0 C.
  • Nt.CviPII showed lowest activity at 65°C, probably due to partial thermal denaturation.
  • the cleavage product of pUC19 appears to be ⁇ 200 bp in 1.5% agarose gel electrophoresis (Fig. 4B).
  • a time course experiment at 37 0 C established that a stable cleavage pattern was reached by 1 hr incubation. Longer incubation times or increasing the enzyme concentration did not alter the appearance of this pattern. Also, the pattern is not the result of Nt.CviPII inactivation at 37°C because pre-incubation of Nt.CviPII at 37°C for 90 min did not alter subsequent enzyme activity.
  • Nt.CviPII activity is defined as the amount of enzyme needed to cleave pUC19 into ⁇ 200 bp products in 1 hr at 37°C, as judged by electrophoresis in 1.5% agarose gels. Protein concentrations were determined by the Bradford assay (Bio- Rad Protein Assay, Bio-Rad Laboratories, Hercules, CA) using BSA as a standard. The specific activity of HiS + -Nt. CviPII is 9410 units/mg of protein.
  • Nt.CviPII cleavage sites in pUC19 are apparently less susceptible to cleavage than others (see below).
  • the ability of Nt.CviPII to cleave single-stranded DNA was also tested. 250 ng of single-stranded M13 phage DNA was incubated with 0.5 or 1 unit of Nt.CviPII at 37°C for 1 hour. Electrophoresis on poly-acrylamide gel containing 7 M urea showed that the single-stranded DNA was partially cleaved by Nt.CviPII.
  • the low cleavage activity of Nt.CviPII on single-stranded DNA is likely due to the nicking activity on the transient duplex form of the phage DNA instead of the cleavage of single-stranded DNA per se.
  • Double-stranded DNA substrates of 189 bp containing single CCA, CCT, CCC or CCG sites at nucleotides 160-162 were constructed by PCR.
  • the substrates contain an internal Xhol site (C ⁇ TCGAG) as a control to monitor cleavage.
  • the substrate DNAs also contain EcoRI and HindIII sites at the 5' and 3' ends, respectively, for ligation into pUC19.
  • the substrate DNA was ligated to pUC19 and the inserted DNA sequence was confirmed by sequencing. Two ug of pUC19-substrate was incubated with Nt.CviPII at 37 0 C for 1 hour.
  • Reactions were terminated by adding 25 mM EDTA and DNA samples were purified by QIAprep spin columns (Qiagen, Valencia, CA). One-eighth dilutions of the purified cleaved products were sequenced with custom primers that anneal at the 5' end of the substrate DNA.
  • DNA oligos were designed such that they served as primers for PCR amplification of two truncation mutants of Nt.CviPII.
  • the primers also added Ndel and Sapl sites at the
  • NPN297 NP Ndel-F and NPN297-SapIR
  • NPN829 Np Ndel-F and NPN329-SAPIR
  • AAAG 3' (SEQ ID NO:23)
  • NPN297 and NPN329 were generated such that they contains the first 297 aa (C-terminal deletion of 51 aa residues) and 329 aa (C-terminal deletion of 19 aa residues) of Nt.CviPII, respectively.
  • the amplified DNA was ligated to pTXBl (New England Biolabs, Inc., Ipswich, MA) at Ndel and Sapl sites.
  • the mutant proteins were expressed as C-terminal fusion to intein Mxe GyrA followed by a chitin-binding domain.
  • the ligated DNA was sequenced to confirm that there was no secondary mutation.
  • the constructs pTXBl-NPN297 and pTXBl-NPN329 were transferred to E. coli strain ER2566 (New England Biolabs, Inc., Ipswich, MA) and grown in LB media or agar plates containing 100 ⁇ g/ml of Amp.
  • NPN297 For purification of the truncated mutant nicking endonucleases, the following protocol was used for NPN297 and may also be used for NPN329.
  • Single colony was inoculated to a starter culture of 100 ml of LB media containing 100 ⁇ g of Amp and grown at 37°C with 250 rpm for 12-16 hours.
  • Ten ml of the starter culture was inoculated to 1 liter of fresh LB media containing 100 ⁇ g of Amp for 6 liters of media.
  • the culture was incubated at 37°C with 250 rpm until OD600 reached 0.6-0.9.
  • IPTG was added to the culture at a final concentration of 0.25 mM/L and incubation was continued for 3 hours at 37°C with 250 rpm.
  • the cultures were centrifuged at 3,550 g at 4°C for 15 minutes.
  • the cell pellets were stored at -2O 0 C.
  • the frozen cell pellets from each liter of culture were resuspended in 15 ml of 20 mM Tris-HCI,
  • the resuspended cells were lysed by sonication on ice.
  • the lysate was centrifuged at 26,70Og for 20 min at 4°C.
  • the supernatant of the lysate was loaded to a chitin column (20 ml bed volume) at 4 0 C.
  • the column was flushed with 40 ml of chitin column buffer with 40 mM of DTT within 10 minutes to induce cleavage of the intein.
  • the column was incubated at 25°C for
  • the cleaved protein was collected by washing the column with 40 ml of chitin column buffer without DTT.
  • the eluted protein solution was diluted one-fourth using 20 mM Tris-HCI, pH 7.7 such that the sodium chloride concentration decreased to ⁇ 125 mM.
  • the column was washed with 300 ml of a buffer containing 20 mM Tris-HCI, pH 7.7 and then with a linear gradient of 0 - 1 M NaCI in 20 mM Tris-HCI, pH 7.7.
  • Fractions of 5 ml were collected and analyzed on SDS-PAGE. NPN297 was eluted in 0.6 M or higher concentration of NaCI. Fractions that contains the protein was pooled and dialyzed against 4 L of 10 mM potassium phosphate buffer, 50 mM
  • DNA nicking activity and cleavage specificity of NPN297 and NPN329 were assayed essentially the same way as for the wild-type Nt.CviPII (Example 2).
  • the truncation mutants were found to be active with the same cleavage specificity as the wild-type Nt.CviPII.
  • NPN297 and NPN329 are estimated to be 2,600 units/mg and 1,400 units/mg, respectively, compared to 9,410 U/mg of the wild- type Nt.CviPIL
  • specific activity of the truncation mutants are lower than the wild-type Nt.CviPII, the yield of the truncation mutants are much higher such that the truncation mutant generates more units of activity from the same volume of culture than the wild type.
  • Example 4 Isothermal amplification of DNA using Nt.CviPII and DNA polymerases with strand displacement activity
  • Nt.CviPII and NPN297 were used in conjunction with several DNA polymerases in isothermal random DNA amplification.
  • DNA polymerase or 4 units of Vent DNA polymerase in ThermoPol reaction buffer at 55°C (20 mM Tris-acetate, 10 mM KCI, 10 mM (NhU) 2 SO 4 , 2 mM MgSO 4 , 0.1% Triton X-100, pH 8.5), or 10 units of Klenow fragment of E. coli DNA polymerase I in EcoPol buffer (10 mM Tris-HCI, 5 mM MgCI 2 , 7.5 mM DTT, pH 7.5) at 37°C for 30 min supplemented with 0.1 mM dNTP.
  • the amplified DNAs were analyzed by electrophoresis on either 1.5%-2% agarose gel or 6% polyacrylamide gel containing 7 M urea in IX TBE buffer.
  • E. coli DNA was incubated with Nt.CviPII and various DNA polymerases and dNTPs at various temperatures for 30 min.
  • Nt.CviPII Bst DNA polymerase I large fragment generated the highest yield of DNA at 55°C.
  • the large fragment of DNA polymerase I from Thermomicrobium roseum (U.S. patent number 5,962,296) also synthesized significant amounts of DNA while the addition of Taq DNA polymerases and Vent DNA polymerase did not result in any detectable DNA synthesis (Fig. 7A). Klenow fragment of E. coli DNA polymerase with Nt.CviPII generated a small amount of amplified DNA. Random DNA amplification can be achieved from T.
  • thermophilus HB27 and ⁇ DNA in the presence of Nt.CviPII/Bst DNA polymerase I large fragment but not with Bst DNA polymerase (Poll) large fragment alone (Fig. 7B).
  • Fig. 7C the DNA having a Poll site in the range of ⁇ 50 to
  • the DNA mass was amplified approximately 50-fold with 10 ng input DNA generating ⁇ 500 ng amplified small DNA fragments.
  • the Nt.CviPII/Bst DNA pol amplified products can be further amplified by adding [N] ⁇ , [N] 9 , or [N]i 2 random primers together with Bst DNA pol large fragment to the amplification product by incubation at 5O 0 C for 60 min resulting in a second round of amplification which is expected to generate major DNA products in the range of 1 to 2 kb.
  • the amplification steps described above were done at 55°C, other temperatures can be used as long as denaturation of double-stranded DNA is favored.
  • Nt.CviPII makes frequent cuts on the DNA and produces single- stranded products or partial duplex DNA with 5' overhang (3' recessed ends) (Fig. 6).
  • Bst DNA polymerase I large fragment then fills in at the 3' end until it reaches the end of the template.
  • the extended DNA acted as a substrate for Nt.CviPII which, in turn, provided a new substrate for the polymerase, allowing linear amplification.
  • the size of the amplified DNA can be increased or decreased by altering the amount (units) of Nt.CviPII in the amplification reactions.
  • DNA oligonucleotides and fresh Bst DNA polymerase large fragment and dNTPs with the amplified product can result in DNA amplification.
  • the amplified DNA can be purified and used as primers for direct amplification of genomic DNA through isothermal or thermocycling procedures.
  • Randomly amplified DNA has been used as a highly sensitive probe for arrays of DNA oligonucleotides carrying
  • DNA amplification method does not require synthesis of primers and can generate large quantities of single-stranded DNA from a single bacterial colony within a short time frame (e.g. 10 to 30 minutes).
  • this DNA amplification method may not necessarily cover the entire genome.
  • the amplified DNA can be used as a probe to detect target DNA by Southern blotting.
  • the procedure can be adapted for environmental or clinical samples and labels such as biotin or fluorescein can be incorporated into the amplified product by using modified deoxy-nucleotides. Development of timely, sensitive and specific detection methods to identify important pathogens is of great importance in bio-defense and public health.
  • Example 5 The use of frequent nicking endonucleases such as Nt.CviPII and Nt.CviOXI to eliminate contaminant DNA from RNA samples
  • An example of this application is to use frequent nicking endonucleases to remove genomic DNA contamination from RNA samples before reverse transcription and RT-PCR.
  • About 500 ng rat liver total RNA was mixed with 2 ⁇ l CIT 23 VN (50 ⁇ M, New England Biolabs, Inc., Ipswich, MA) and 7 ⁇ l dH 2 O.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Recombinant nicking endonucleases and associated methylases have been obtained and sequenced and their specificity has been defined. A mutant form of the nicking endonuclease has been cloned where the mutation includes deletion of amino acid sequences at the C-terminal end of the protein. The nicking enzymes have been used for a number of purposes including: amplifying DNA from as few cells as can be found in a single bacterial colony in the presence of a strand displacing polymerase; and for removing genomic DNA in a biological preparation where it is deemed to be a contaminant.

Description

Recombinant DNA Nicking Endonuclease and Uses Thereof
BACKGROUND OF THE INVENTION
DNA nicking endonucleases cleave one strand of DNA in a sequence-specific and strand-specific manner. Although there are over 240 type II restriction endonucleases with unique specificities isolated from bacterial and viral sources, only a few site-specific nicking endonucleases are currently commercially available (Roberts et al. Nucl. Acids Res.
31 :418-420 (2003); REBASE). Efforts to develop more nicking endonucleases consist of either genetic engineering from existing restriction endonucleases or screening from bacterial and viral sources. The nicking endonuclease N.BstNBI and N.BstSEI (5' GAGTCN4 A 3') were found in strains of Bacillus stearothermophilus (Morgan et al. Biol. Chem. 381 : 1123-1125 (2000); Abdurashitov et al. MoI. Biol. (Mosk) 30: 1261-1267 ( 1996)) and the nicking endonuclease N.BsrDI (5' ΛCATTGC 3'), the large subunit of BsrDI, was found in the strain B. stearothermophilus D70. Two natural nicking endonucleases Nt.CviPII (ΛCCD) and Nt.CviQXI (RΛAG) from chlorella viruses have been described (Xia et al. Nucl. Acids Res. 16:9477-87 (1988); Zhang et al. Virology, 240: 366-75 (1998)).
The low quantities of Nt.CviPII in NYs-I infected lysate limited the potential application of this nicking endonuclease in DNA manipulation. To overcome this limitation, it would be desirable to clone and express this nicking-modification system. SUMMARY OF THE INVENTION
In an embodiment of the invention, an isolated DNA segment encodes a protein with DNA cleavage activity where the protein has an amino acid sequence that has at least about 25% amino acid sequence identity with SEQ ID NO:29. In a further embodiment, the protein is capable of cleaving, at a specific site, a single DNA strand in a duplex where the specific cleavage site is for example, CCA, CCG or CCT.
The isolated DNA segment may be further characterized as having a DNA sequence with at least about 40% DNA sequence identity with SEQ ID NO:28.
In another embodiment, the isolated DNA segment encodes a protein with DNA cleavage activity where the DNA segment has at least about 10 contiguous bases identical to sequences contained in SEQ ID NO:28. Preferably, a protein of this type is capable of cleaving, at a specific site, a single
DNA strand in a duplex where the specific cleavage site is for example, CCA, CCG or CCT.
In another embodiment, the isolated DNA segment encodes a protein with DNA methylase activity, which shares at least about 47% amino acid sequence identity with SEQ ID NO:31. The sequence of the DNA segment shares at least about 53% DNA sequence identity with SEQ ID NO:30. In additional embodiments, a recombinant nicking endonuclease is provided that has an amino acid sequence sharing at least about 25% sequence identity with SEQ ID NO:29 and a recombinant DNA methylase, is provided which shares at least about 47% amino acid sequence identity with
SEQ ID NO:31.
In an additional embodiment, a recombinant nicking endonuclease is provided wherein the endonuclease is a mutant having a deletion at the C-terminal end. For example, mutants with deletions of about 51 and 19 amino acid residues at the C-terminus end retain their specificity for CCA, CCG and CCT.
In an embodiment of the invention, a vector is provided that includes a segment of DNA, which has a sequence that has at least about 10 contiguous bases identical to sequences contained in SEQ ID NO:28. A host cell containing this vector is also provided.
In an additional embodiment of the invention, a method is provided for amplification of DNA, that includes the steps of incubating the DNA with a DNA polymerase capable of strand displacement and a recombinant nicking endonuclease (as described above) and obtaining amplified DNA. This amplification method can be performed isothermally. An additional amplification step may optionally be added to the method in which random primers and a strand displacement polymerase are added to the amplified DNA to enhance the yield of the amplification by another round of amplification. Examples of polymerases for use in the method include Bst polymerase, Thermomicrobium roseum pol I and E. coli DNA polymerase large (Klenow) fragment. An example of the recombinant nicking endonuclease is Nt.CviPII. The DNA may be obtained from a single bacterial colony.
In an embodiment of the invention, a method is provided for eliminating DNA from a sample of biological material, that includes (a) adding Nt.CviPII nicking endonuclease or mutant thereof to the sample of biological material; and (b) allowing the nicking endonuclease or mutant thereof to cleave the DNA so as to eliminate the DNA from the sample of biological material.
In an embodiment of the invention, a method for cloning a toxic nicking endonuclease is provided that depends on removing a C-terminal sequence from the DNA encoding the toxic nicking endonuclease; and cloning the truncated gene in a suitable host cell such as E. coli. This approach has worked effectively for toxic enzymes cloned from Chlorella viruses.
BRIEF DESCRIPTION OF THE FIGURES
Figure IA shows a cartoon of the CviPII nicking- modification system. This system contains 2332 nucleotides and two complete open reading frames (ORFs). The methyltransferase contains 8 motifs typically found in m5C DNA methyltransferases but lacks motif IX and X that are also typical of methyltransferases from organisms other than chlorella. The nicking endonuclease has two active site motifs that are characteristic of some restriction endonucleases.
Figure IB shows a small amount of Nt.CviPII purified from E. coli analyzed by SDS-PAGE using 4-10% gel. Lane 1 is Nt.CviPII while lane 2 is a molecular weight marker.
Figure 2A shows an alignment of the M.CviPII sequence (SEQ ID No I) with another chlorella methyltransferase (M.CviPI) sequence (SEQ ID. No. 2) and a bacterial methyltransferase (M.Hhal) sequence (SEQ. ID. No 3).
Motifs I through X of m5C methyltransferase are marked. Conserved residues in the motifs are indicated by dots. Sequences that are identical are shown in black boxes.
Conserved but not identical residues are shown in grey boxes. Asterisks indicate catalytic residues and hashes indicate S- adenosyl-L-methionine binding residues.
Figure 2B shows the amino acid sequences for Nt.CviPII
(SEQ ID NO:4) and restriction endonuclease CviJI (SEQ ID NO:5). Sequences that are identical are shown in black boxes. Conserved but not identical residues are shown in grey boxes.
Two type II restriction endonuclease active site motifs
(P-D/E-Xn-D/E/S-Z-K/E where Z = hydrophobic residue) are found in Nt.CviPII sequences namely (i) Serl26-Aspl27-Xi2- Glul39-Ilel40-Lysl41 and (ii) V189-Glul90-X2i-Glu211- Val212-Lys213. The latter motif can be partially aligned to the proposed active site of CviJI. Asterisks indicate conserved residues of the active site motif.
Figure 3A shows the results of the experiment that probes the putative M-CviPII methylation site. The DNA is p\JC-cviPIIM expressing M-CviPII. The DNA was isolated and digested with Mspl or ScrFI. The first cytosine at the Nt-CviPII cleavage site of CCD was shown to be methylated because the plasmid was cleaved by ScrFI but was resistant to Mspl digestion.
Figure 3B is a chromatogram showing target sequences for methylation by M-CviPII. PCR products derived from sodium bisulfide-treated p\JC-cviPIIM are compared to those from un-treated p\JC-cviPIIM. The change of cytosine to thymidine corresponds to unmodified cytosine, whereas the presence of cytosine in both sodium bisulfide-treated and un¬ treated DNA indicates C5-methylcytosine. Results for recognition sites CCT, CCG (SEQ ID NOS:8 and 9), CCA (SEQ ID NOS: 10 and 11), CCCG (SEQ ID NOS: 12 and 13) show that the first Cs are methylated in CCN triplets. The result for CCAA (SEQ ID. No. 14 and 15) show relaxed specificity towards the second C of CCAA. The modified nucleotides are indicated by down arrows.
Figure 4A compares the results from IPTG-induced Nt.CviPII expression and un-induced cell extract under a lac promoter on pUC19 DNA. Supernatant of the lysate of induced (upper panel) and un-induced culture (lower panel) from equivalent cultures were loaded on a SP FF column and eluted with linear gradient of 0.1-1 M NaCI. High DNA nicking activity was obtained with IPTG induction. N= relaxed circle, L=linear and S= supercoiled.
Figure 4B shows that Nt.CviPII is surprisingly thermostable being active at least to temperatures of 6OC. 0.5 μg of pUC19 was incubated with 1 unit of Nt.CviPII for 1 hour at various temperatures (lanes 2-10). The reactions were stopped and analyzed by electrophoresis on 1.5% agarose gel. Lane 11 is linearized pUC19 DNA, lane 12 is supercoiled pUC19 DNA and lanes 1 and 13 are 100 base pair size markers.
Figure 4C shows the results of Nt.CviPII-cleaved pUC19 and single stranded M 13 phage DNA by electrophoresis on 6% poly-acrylamide gel with 7 M urea. Lane 1 : size marker.
Lane 2: pUC19 (double strand DNA) with 1 unit of Nt.CviPII. Lane 3 : M13 (single strand DNA) with 1 unit of
Nt.CviPII.
Lane 4: M 13 (single strand DNA) with 0.5 units of Nt.CviPII.
Lane 5: M 13 (single strand DNA) with 0 units of Nt.CviPII.
Lane 6: LMW: low molecular weight DNA size marker.
Figure 5 shows that CCA and CCG are the preferred substrates (SEQ ID NOS: 18 and 19) for Nt-CviPII cleavage. Nt.CviPII does not cleave at CCC but instead cleaves at the overlapping CCA site (SEQ ID NO:20). CCT shows low-level cleavage by Nt-CviPII (SEQ ID NO: 21).
The upper schematic shows the sequence that was nicked by Nt.CviPII and read as the reverse-complement by the sequencing primer. Therefore, TGG corresponds to CCA, CGG to CCG, GGG to CCC and AGG to CCT. Triplet sequences in boxes are CCN sites designed on the substrate DNA. Native CCA sequences of pUC19 are underlined. The arrowheads indicate the cleavage site. The arrows under the chromatographs and the bracketed "a" in the schematic indicate the adenine added by the template-independent activity of Taq DNA polymerase used in sequencing reactions at the cleavage site.
Figure 6 shows a schematic outline of isothermal amplification using Nt.CviPII and Bst DNA polymerase I large fragment.
Figure 7A shows that nicking-endonuclease mediated isothermal amplification of DNA prefers a DNA polymerase with strand displacement activity. Purified E. coli DNA was incubated with Nt.CviPII in combination with Bst DNA polymerase I large fragment (Bst), T. roseum (Tro), Vent DNA polymerase, T. aquaticus (Taq) or E. coli DNA polymerase I
Klenow fragment (Klenow) in the presence of dNTPs. Only Bst polymerase and Tro polymerase amplified the DNA significantly. Klenow also amplified low levels of DNA. No detectable amplification was found using Vent or Taq or no polymerase. Figure 7B shows the results of isothermal amplification of purified DNA from T. thermophilus and λ phage. T. thermophilυs and λ DNAs were amplified with Nt.CviPII and Bst DNA polymerase I large fragment. The amplified products were analyzed by 1.5% agarose gel electrophoresis. Lanes 2 and 4 shows the results of amplification only in the presence of both enzymes. Lane 5 is a marker. Lanes 1 and 3 show results from an amplification reacton containing only Bst DNA polymerase I large fragment and no Nt.CviPII. No detectable
DNA was amplified without Nt.CviPII.
Figure 7C shows that on 10-20% polyacrylamide gel with 7 M urea, the amplified DNA from Figure 7B are resolved into single-stranded DNA from < 25 to over 500 nt.
Figure 7D shows that DNA can be amplified from a single bacterial colony subjected to heat treatment to release the DNA. Only a fraction of DNA was amplified without heating the cells (lane 6).
Lane 1 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment, CviPI and Nt.CviPII.
Lane 2 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment, and
Nt.CviPII.
Lane 3 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment only. Lane 4 is the heat-treated cells from a single colony incubated with Bst DNA polymerase I large fragment, Mspl and Nt.CviPII.
Lane 5 is Bst DNA polymerase I large fragment, and Nt.CviPII with no DNA template.
Lane 6 is the non-heat treated cells from a single colony incubated with Bst DNA polymerase I large fragment, and Nt.CviPII.
Figure 8 shows DNA nicking activity of two Nt.CviPII truncation mutants. Four-fold dilutions of NPN297 or NPN329 (1 unit, 0.25 units, 0.06 units and 0.02 units) were incubated with 1 μg of pUC19 DNA at 370C for 1 hour. The cleavage products were analyzed on a 1.5% agarose gel in TBE. Supercoiled (SC) and linearized (L) pUC19 DNA and a marker were included for comparison.
Figure 9 shows the results of Nt.CviPII truncation mutant-mediated DNA amplification. NPN297 (0.25 units) was used in combination with Bst DNA polymerase I large fragment (2 units) in the presence of 0.2 mM dNTPs and designated amount of λ DNA. The reactions were carried out at 55°C for 30 minutes.
Figure 10 shows the efficient removal of genomic DNA by
Nt.CviPII in reverse transcription reactions.
Lane M : 2-log DNA ladder (New England Biolabs, Inc., Ipswich, MA).
Lane 1 : reverse transcription (RT) without M-MuLV reverse transcriptase; Lanes 2 and 4: RT with M-MuLV reverse transcriptase; Lane 3: RT without M-MuLV reverse transcriptase, but in the presence of 0.5 unit of Nt.CviPII;
Lane 5: RT without M-MuLV reverse transcriptase, but in the presence of 2 units of Nt.CviPII.
Figure HA shows the DNA sequence of the CviPINt. gene (SEQ ID NO:28).
Figure HB shows the amino acid sequence of the CviPIINt. gene (SEQ ID NO:29).
Figure 12A shows the DNA sequence of the CviPIIM gene (SEQ ID NO:30).
Figure 12B shows the amino acid sequence of the CviPIIM gene (SEQ ID NO:31).
DETAILED DESCRIPTION OF THE INVENTION
The cloning and expression of CviPII nicking- modification system, purification of Nt.CviPII, and its utility in generating DNA oligonucleotides for random DNA amplification are described here. A significant aspect of this work is overcoming a toxicity problem caused by the frequent DNA nicking activity of the enzyme so as to produce a sufficient amount of recombinant Nt.CviPII, for its use as a molecular biology reagent. Nt.CviPII is of interest for a number of reasons including its ability to recognize a three- base sequence (CCD; D = A, G or T) of double strand DNA at the 5' end of the first C of the top strand. It is also a naturally occurring frequently cutting nicking endonuclease. These properties have been exploited in a number of ways including a method of primer independent isothermal DNA amplification.
The nicking endonuclease Nt.CviPII described here has been cloned from a chlorella virus referred to as NYs-I. The CviPII nicking and modification system was cloned and expressed in E. coli. Initially, the cviPIIM gene was cloned in
E. coli by the methyltransferase selection method. The adjacent ORFs were sequenced directly from the viral DNA. A downstream ORF showed some amino acid sequence identity to a restriction endodnuclease CviJI (RGΛCY) in a BlastP search of all known genes in GeneBank.
An ORF for Nt.CviPII was identified, amplified by PCR and transcribed and translated in an in vitro transcription and translation system. The cell free extract showed DNA nicking activity when it was compared to the native Nt.CviPII nicking endonuclease. However, it proved difficult to produce large amounts of protein for further characterization. Therefore, more efforts were made to express cviPIIM and cviPIINt genes in E. coli. E. coli expression host ER2683 was pre- modified by introduction of plasmid pUC-cv/PiTM, and the cviPIINt gene was cloned in the expression vector pR976, a low copy number plasmid with Ptac promoter. Extra codons were added to the 5' end of cviPIINt gene to incorporate a tag of 6 histidine residues to facilitate purification of the protein. To minimize the toxicity of the nicking endonuclease associated with its ability to nick DNA every 50-60 bp, the nicking endonuclease gene was positioned 18 nucleotides downstream of the ribosome-binding site to reduce the level of translation. Recombinant Nt.CviPII production was induced by the addition of IPTG to the culture media. Nt.CviPII was purified through affinity-tag purification and traditional chromatography such as metal-chelation chromatography, heparin FF and ion-exchange chromatographies. The purified Nt.CviPII revealed a nicking site preference of CCR>CCT (R =
A or G) and was active through a wide temperature range with highest activity at a temperature range of 30-450C while retaining activity at 550C and 6O0C.
M.CviPII was shown to modify the first Cs in CCA, CCG,
CCT and CCC triplet sequence (Example 1). It also modified the first two Cs in the sequence of CCAA (Fig. 3B).
To further increase the amount of Nt.CviPII obtained by recombinant technology, two C-terminal truncation mutants of Nt.CviPII fused to an intein and chitin-binding domain were geberated. The combination of truncation and fusion decreased the toxicity of the nicking endonuclease to the host cells so that the fusion protein was over-expressed in E. coli strain ER2566 (New England Biolabs, Inc., Ipswich, MA). The fusion proteins were purified by chitin column chromatography and the fusion part was removed by self- cleavage activity of the intein induced by reducing agent. The cleaved Nt.CviPII truncation mutants were further purified by standard chromatographic steps. The truncation mutants of Nt.CviPII were found to possess the same sequence specificity but lower specific activity than the wild-type enzyme.
Uses of Nt.CviPII
(a) Isothermal amplification
Due to the high frequency of Nt.CviPII cleavage sites and its partial duplex cleavage product, Nt.CviPII was used in conjunction with several DNA polymerases in isothermal random DNA amplification. An assay system was developed to determine conditions for isothermal amplification. This assay system is described in Example 3. Using this approach, it is possible to show amplification of a DNA using Nt.CviPII and
DNA polymerases possessing strand-displacement activity. Moreover, Figure 6 shows that DNA can be amplified from a single bacterial colony.
Nt.CviPII may also be used in prior art methods of isothermal amplification that utilize nicking endonucleases. These include: strand displacement amplification, exponential DNA amplification (EXPAR) or nick translation with DNA polymerases such as Klenow fragment, Bst DNA polymerase, Thermomicrobium roseum DNA pol I large fragment, or phi 29
DNA polymerase to replicate DNA at the nicked sites.
(b) Amplifying DNA from single colonies DNA can be amplified from a single E. coli colony using Nt.CviPII and a strand displacement DNA polymerase (Figure 7D). The cells in the single colony have been broken by heat to release DNA but any other method in the art can be used where preferably no additional purification steps are required before performing amplification.
(c) Removing genomic DNA from RNA or protein preparations
DNase I is the most commonly used enzyme in DNA contaminant removal from RNA samples. DNase I is a non¬ specific nicking endonuclease that works on single-stranded DNA, double-stranded DNA, and DNA-RNA hybrids. After DNAse I treatment, the enzyme must be removed from the
RNA sample before other applications such as RT-PCR. However, DNase I is heat-resistant and therefore phenol extraction is required to remove DNase I completely (Aguila et al. BMC Molecular Biology 6:9 (2005)). In contrast, Nt.CviPII is a sequence-specific nicking endonuclease that recognizes double-stranded DNA only. Therefore, the DNA contaminant removal can be done by Nt.CviPII simultaneously with the reverse transcription reaction so that no extra purification steps are required. By choosing a different frequent nicking endonuclease, a different digestion pattern can also be achieved.
(d) Creation of gaps for assembling DNA molecules and for purifying DNA The nicking endonucleases described herein may be used for creating single-stranded regions in duplex nucleic acids. Such single-stranded regions can take the form of gaps interior to the duplex, or terminal single-stranded regions. Single-stranded termini can be crafted to allow linkage of various elements via base-pairing with elements containing a complementary single-stranded region. This joining is useful, for example, in an ordered, oriented assembly of DNA modules to create cloning or expression vectors. This joining is also useful in attaching detection probes and purifying DNA molecules containing the single-stranded region. Gaps are useful in similar applications, including attaching detection or purification probes (U.S. Patent No. 6,660,475 and U.S. Patent Publication No. 2003-0194736 Al herein incorporated by reference).
(e) Labeling DNA
The nicking endonucleases described herein can be used to label DNA. At first, nicks are introduced into DNA by
Nt.CviPII. Then DNA polymerases with strand displacement activity can be used to replicate DNA. Radioactive dNTP, biotinylated dNTP, or dNTP with fluorophore modification can be added in the DNA extension reaction. The newly synthesized DNA should be labeled according to the dNTP used.
(f) Detecting mutations Similarly to restriction fragment polymorphism to detect genetic alterations, nicking fragment DNA polymorphism can be used to detect gene mutations if the point mutation takes place within the nicking site recognition sequence.
(g) Creating relaxed circles from supercoiled DNA
The nicking endonucleases described herein can be used to prepare relaxed circular DNA under limited nicking conditions, e.g., using diluted Nt.CviPII. Supercoiled plasmid
DNA is first nicked by Nt.CviPII provided that the plasmid contains at least one CCD site. The supercoiled DNA should be converted to nicked-open circular DNA, which can be gel- purified. The purified nicked DNA is treated with DNA ligase to generate relaxed circular DNA.
The references cited above and below as well as U.S. provisional application serial number 60/620,939 are hereby incorporated by reference herein.
Example 1: Cloning and identification of cvi PII M and cviPIINt
Chlorella virus NYs-I genomic DNA was digested partially with Sau3AI and ligated to a BamHI-digested and
CIP-treated pUCAC (a derivative of pUC19 by inserting a PCR- amplified chloramphenicol resistant gene into AfIIII site of pUC19) and the ligated DNA was used to transform ER1992 competent cells to construct a Sau3AI genomic DNA library. Approximately 105 ampicillin resistant transformants were pooled and plasmid DNA was prepared. Clones that expressed M.CviPII methylase were selected by digesting pooled ampicillin and chloramphenicol resistant plasmids with Mspl (cleaves CCGG and CmCGG sequences but not mCCGG sequence). Eighteen plasmids from the Sau3AI genomic library were found to be partially resistant to Mspl digestion. The inserts of six isolates were sequenced, which revealed an identical open reading frame (ORF, 1092 bp) that had 45.2% amino acid (aa) identity to the NYs-I encoded M.CviPI
(recognition sequence GC) and 41% amino acid identity to chlorella virus IL-3A encoded M. CvUI (recognition sequence RGCY) (Xu et al. NucL Acids Res. 26:3961-66 (1998); Shields et al. Virology 176: 16-24 (1990)) (Fig. 2A). The presence of most of the conserved motifs of m5C methylases in the primary structure of M.CviPII indicates that M.CviPII is a m5C methylase (Chan et al. Nucl. Acids Res. 32:6187-6.199 (2004)).
The putative cviPIIM gene was amplified by PCR and ligated into pUC19 at the Sphl and Sail sites and transferred into E. coli ER2502. In vivo activity of M.CviPII was tested by challenging the plasmid isolated from ER2502 [p\JC-cviPIIM]. The plasmid was incubated with Mspl (CACGG) or ScrFI (CCΛNGG) at 37°C for 1 hour in NEBuffer 2 (10 mM Tris-HCI,
50 mM NaCI, 10 mM MgCI2, 1 mM DTT, pH 7.9), New England Biolabs, Inc., Ipswich, MA. The digested DNA was analyzed by agarose gel electrophoresis. The plasmid p\JC-cviPIIM was partially resistant to Mspl but not to ScrFI (Fig. 3A). Mspl cleaves CmCGG, but not mCCGG, whereas ScrFI cleaves "1CCNGG, but not CmCNGG (http://rebase.neb.com/rebase). This indirect evidence (resistant to Mspl digestion) indicated that M.CviPII modifies the first cytosine of the CCGG sequence, which is consistent with the result obtained from the native enzyme (Xia et al. Nucl. Acids Res. 16:9477-9487
(1988)).
To determine the site of modification, the plasmid pUC- cviPIIM used in methylase protection assay was treated with sodium bisulfide (EZ DNA Methylation Kit, Zymo Research
Corporation, Orange, CA). The sodium bisulfide-treated DNA was purified by Qiaprep spin-columns (Qiagen, Valencia, CA) and used for PCR using primers that amplified the cviPIIM gene (MP-Sphl-F and MP-SaII-F).
MP-Sphl-F
CGGTAAGCSATGCATGCGTACAAAGTATCGTA I I I I I ATCGTATGT
ATG (SEQ ID NO:7)
MP-SaII-R
GAAGTCGACTTAATAATGCATAAGATCACCCAAATATTCGTCG (SEQ ID NO:22)
Untreated plasmid was also amplified by the same pair of primers as control. Methylated cytosines were protected from sodium bisulfide that converted un-modified cytosines to uracils, which are amplified as thymidines in PCR. Thus, by comparing with control PCR product, cytosine residues that became thymidines were un-modified while those that remained cytosines were methylated. Sequencing of PCR-amplified DNA from the sodium bisulfide-treated pUC-cviPIIM indicated that most of the first but not the second cytosine of CCG, CCA and CCT are modified (Fig. 3B). Surprisingly, the first two cytosines in
CCCG and CCAA were also modified (Fig. 3B, Table 2). In CCCG where CCC and CCG overlap, methylation of the first C in CCCG indicated that M.CviPII also methylates CCC site, a result of relaxed methyltransferase activity. Modification of the first and second Cs in CCAA suggested that M.CviPII modifies cytosine in relaxed recognition sequence under over- expressed condition (the cviPIIM gene was cloned in a high- copy-number plasmid and IPTG-induced).
NYs-I DNA adjacent to cviPIIM gene was sequenced and an ORF of 349 codons was identified (in the same orientation) that began 12 nucleotides downstream of the cviPIIM stop codon (Fig. IA). The protein expressed from the ORF had low but significant amino acid sequence identity to chlorella virus IL-3A encoded restriction endonuclease CviJI (RG/CY, with
18.3% identity (Fig. 2B)) which may reflect overlapping recognition sequence. The half site of CviJI (CY, Y = C or T) is similar to Nt.CviPII recognition sequence CCD. However, Nt.CviPII does not show significant similarity to other restriction endonucleases or nicking endonucleases with overlapping recognition sequence in GenBank. The pi value of Nt.CviPII was calculated to be 9.82 by ProtParam Tool of ExPASy Proteomics server of Swiss Institute of Bioinformatics. Example 2: Expression and purification of Nt.CviPII
Due to the frequent Nt.CviPII nicking sites, difficulties in cloning the cviPHNt gene in E. coli were encountered. Initially, Nt.CviPII was expressed using in vitro transcription and translation system. A low level of nicking activity was detected in the lysate in comparison with the native Nt.CviPII. However, it was difficult to achieve a clear digestion pattern. To achieve sufficient enzyme for purification, the Nt.CviPII system was modified for expression in E. coli. The expression host ER2683 was pre-modified by expression of M.CviPII via introduction of pUC-cviPIIM. Additional measures were taken to construct a stable expression clone: (i) A low copy number plasmid pR976 with Ptac (pl5A replication origin) was used as the cloning vector for the cviPIINt gene; (ii) The cviPIINt gene was inserted 18 nucleotides downstream of the ribosome- binding site so as to reduce the expression level of the enzyme. The efforts to express M.CviPII in pACYC184 (pACYC-cwPJ/M gave marginal modification of host genomic DNA] and Nt.CviPII in pET21a vector failed to generate a stable expression clone.
The expression strain ER2683 [pUC-cviPIIM, pR976- cviPIINt] was successfully constructed. M.CviPII that was constitutively expressed under the control of lac promoter on pUCAC protected the host DNA from basal expression of the Nt.CviPII. The Nt.CviPII expression plasmid alone could not transform E. coli cells, indicating that the residual expression of Nt.CviPII in the absence of the cognate methyltransferase is lethal to the host. To determine the basal level of expression, induced or un-induced cultures of the expression strain ER2683 [pUC-cviPIIM, pR976-cviPIINt] were grown and partially purified by anion-exchange chromatography. The fractions were tested for DNA nicking activity.
A single colony of ER2683 [pUC-cw'PIZΛf, pR976- cviPIINt] was grown to mid-log phase in 2 liters of rich medium (10 g/l Tryptone, 5 g/l yeast extract, 5 g/l NaCI, pH adjusted to 7.2 with NaOH) containing Amp (0.1 mg/ml), kanamycin (Km, 0.05 mg/ml) and tetracycline (Tc, 0.01 mg/ml) at 300C at 280 rpm. One liter of culture was induced with 0.25 mM IPTG and the other was not. Both cultures were incubated at 16°C for 18 hr and cells were harvested by centrifugation. The cell pellets (wet weight of 3.9 g for the induced culture and 5.0 g for the un-induced culture) were sonicated in 100 ml of 20 mM sodium phosphate, 0.1 M NaCI, pH 7.4. After centrifugation, the soluble fractions were loaded on a SP FF (25 ml bed volume, Amersham Biosciences, now GE Healthcare, Uppsala, Sweden) column and eluted with a linear gradient of 0.1-1 M NaCI. Two μl of the fractions were incubated with 0.5 mg of pUC19 at 37°C for 1 hr. Reactions were stopped by adding 25 mM EDTA and analyzed by agarose gel electrophoresis. DNA nicking activity was distinguished from non-specific host nucleases. Non-specific nucleases produce a smear while Nt.CviPII produces a characteristic banding pattern of the digested DNA.
In the presence of IPTG, fractions eluting from a SP FF column exhibited significantly higher DNA nicking activity (Fig. 4A, top panel) than fractions from the un-induced culture (Fig. 4A, bottom panel). The un-induced culture, nevertheless, showed significant DNA nicking activity, indicating that there was basal expression of Nt.CviPII in the absence of IPTG. IPTG induction of cells grown at 16°C produced more Nt.CviPII activity than cells grown at higher temperatures.
To purify the recombinant His-tagged Nt.CviPII, the supernatant obtained after sonication was loaded into a nickel-charged HisTrap column (HisTrap HP, 5 ml bed volume,
Amersham Biosciences, now GE Healthcare, Uppsala, Sweden) and protein was eluted with a step gradient of 50, 100, 200, 300, 400 and 500 mM imidazole in 20 mM NaHPO4, 0.5 M NaCI, pH 7.4. DNA nicking activity was detected in fractions eluting in 50 mM and 300 mM imidazole. The 50 mM imidazole fraction was further purified on a heparin FF (25 ml bed volume, Amersham Biosciences, now GE Healthcare, Uppsala, Sweden) column and a SP FF (25 ml bed volume, Amersham Biosciences, now GE Healthcare, Uppsala, Sweden) column. The 300 mM imidazole fraction was concentrated and assayed. All purified protein preparations were concentrated by VIVASPIN 20 (10,000 MWCO, VIVASCIENCE) and stored in 10 mM NaHPO4, 250 mM NaCI, pH 7.0 with 50% glycerol at -2O0C.
N-terminal sequencing of the purified protein eluted in 50 mM imidazole revealed a MSTPQAKTKYY sequence (SEQ ID NO:6), which corresponds to amino acids 5 to 15 in Nt.CviPII. Thus this fraction contains a protein initiated at the fifth codon of cviPIINt, which is an ATG. Mass spectrometry showed that the mass of this protein is 34, 110 Da, compared to the predicted value of 40,069 Da. This preparation was designated His"-Nt.CviPII.
Protein that eluted at 300 mM imidazole was concentrated and two bands of ~34-36 kDa were observed by SDS-PAGE. N-terminal sequencing established that the upper band was Nt.CviPII with a 6-Histidine tag while the lower band was an E. coli 2-dehydro-3-deoxyphosphoheptonate aldolase contaminant. The two proteins were separated cleanly on a SP FF column, resulting in pure Nt.CviPII as judged by SDS-PAGE (Fig. IB). This protein was designated HiS+-Nt. CviPII. Because this latter preparation was cleaner than His -Nt.CviPII, it was used in all subsequent experiments.
Nt. CviPII nicking endonuclease activity
Nt.CviPII activity was measured at 16°C, 200C, 250C, 3O0C, 370C, 45°C, 550C, 6O0C and 65°C on 0.5 ug of pUC19 substrate in NEBuffer 4 (20 mM Tris-acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 1 mM DTT, pH 7.9, New England Biolabs, Inc., Ipswich, MA) (Fig. 5A). DNA nicking activity was highest at 30-450C, whereas the activity at 20-250C was higher than that at 55-600C. Nt.CviPII showed lowest activity at 65°C, probably due to partial thermal denaturation. At 30-450C, the cleavage product of pUC19 appears to be ~200 bp in 1.5% agarose gel electrophoresis (Fig. 4B). A time course experiment at 370C established that a stable cleavage pattern was reached by 1 hr incubation. Longer incubation times or increasing the enzyme concentration did not alter the appearance of this pattern. Also, the pattern is not the result of Nt.CviPII inactivation at 37°C because pre-incubation of Nt.CviPII at 37°C for 90 min did not alter subsequent enzyme activity.
Extended incubation of pUC19 with both batches of Nt.CviPII (HiS+ and His") for 16 hours indicated that there is no significant contamination of non-specific nuclease. One unit of Nt.CviPII activity is defined as the amount of enzyme needed to cleave pUC19 into ~200 bp products in 1 hr at 37°C, as judged by electrophoresis in 1.5% agarose gels. Protein concentrations were determined by the Bradford assay (Bio- Rad Protein Assay, Bio-Rad Laboratories, Hercules, CA) using BSA as a standard. The specific activity of HiS+-Nt. CviPII is 9410 units/mg of protein.
Analyzing the pUC19 cleavage products by electrophoresis on poly-acrylamide gel containing 7 M urea indicated that the single-stranded DNA fragments were smaller than 150 nucleotides in size (Fig. 4C). There are 252
CCD sites on both strands of pUC19. With 2686 base pair and assuming that nicking sites are equally distributed in both strands, complete cleavage of pUC19 gives fragments of ~20 nucleotides long. However, the end products of pUC19 are single-stranded DNA ranged from 25 to 150 nt as shown in
Fig. 4B, suggesting that some of the sites are not cleaved. Therefore, some Nt.CviPII cleavage sites in pUC19 are apparently less susceptible to cleavage than others (see below). The ability of Nt.CviPII to cleave single-stranded DNA was also tested. 250 ng of single-stranded M13 phage DNA was incubated with 0.5 or 1 unit of Nt.CviPII at 37°C for 1 hour. Electrophoresis on poly-acrylamide gel containing 7 M urea showed that the single-stranded DNA was partially cleaved by Nt.CviPII. The low cleavage activity of Nt.CviPII on single-stranded DNA is likely due to the nicking activity on the transient duplex form of the phage DNA instead of the cleavage of single-stranded DNA per se.
Nt.CviPII cleavage specificity
Double-stranded DNA substrates of 189 bp containing single CCA, CCT, CCC or CCG sites at nucleotides 160-162 (Table 1) were constructed by PCR. The substrates contain an internal Xhol site (C^TCGAG) as a control to monitor cleavage. The substrate DNAs also contain EcoRI and HindIII sites at the 5' and 3' ends, respectively, for ligation into pUC19. The substrate DNA was ligated to pUC19 and the inserted DNA sequence was confirmed by sequencing. Two ug of pUC19-substrate was incubated with Nt.CviPII at 370C for 1 hour. Reactions were terminated by adding 25 mM EDTA and DNA samples were purified by QIAprep spin columns (Qiagen, Valencia, CA). One-eighth dilutions of the purified cleaved products were sequenced with custom primers that anneal at the 5' end of the substrate DNA.
When a nick occurs in a double-stranded DNA, sequencing reaction on the nicked strand stops after the nicked base and the peaks in the sequencing chromatogram diminish sharply (Run-off sequencing). An extra adenine is added to the 3' end of the newly synthesized single-stranded DNA due to the template-independent polymerase activity of Taq DNA polymerase used in the sequencing reaction. The adenine peak also helps identify the cleavage site. Consistent with a previous report (Xia et al. Nucl. Acids Res. 16:9477-87 (1988)), run-off sequencing showed that the DNA was cleaved 5' of the first cytosine in CCA, CCG and CCT sequences, but not at the CCC site (Fig. 5). However, cleavage is less favorable at the CCT site than the CCA and CCG sites as only a small amount of the CCT substrate was cleaved (Fig. 5, bottom panel). A small peak of adenine following the AGG triplet indicates that some cleavage occurred at the CCT site. Cleavage occurred between the first and the second cytosine in the CΛCCA sequence. No cleavage took place before the first C in CCCA sequence. In all experiments, a minor peak corresponding to adenine signified the end of the template.
Example 3. Truncation mutants of Nt.CviPII: Cloning. expression, and purification of C-terminal truncation mutants of Nt.CviPII
DNA oligos were designed such that they served as primers for PCR amplification of two truncation mutants of Nt.CviPII. The primers also added Ndel and Sapl sites at the
5' and 3' end of the amplified DNA, respectively, for cloning purposes: NPN297 (NP Ndel-F and NPN297-SapIR) and NPN829 (Np Ndel-F and NPN329-SAPIR). NP-Ndel-F
5' ACCGTTGAGCAIAIGTATATATATATGTCTACTCCGCAGGC
AAAG 3' (SEQ ID NO:23)
NPN297-SapI-R
5' GGTGGTTGCTCTTCCGCAACAGGAAGAAGAAATTAATTCTATTT TA I I I I I CAAAACATCATCGAT 3' (SEQ ID NO: 24)
NPN329-SapI-R
5' GGTGGTTGCTCTTCCGCAGCATTTTGGTGGACTTGTTATTTTCT TTGATTTTGG 3' (SEQ ID NO:25)
Mutants NPN297 and NPN329 were generated such that they contains the first 297 aa (C-terminal deletion of 51 aa residues) and 329 aa (C-terminal deletion of 19 aa residues) of Nt.CviPII, respectively. The amplified DNA was ligated to pTXBl (New England Biolabs, Inc., Ipswich, MA) at Ndel and Sapl sites. The mutant proteins were expressed as C-terminal fusion to intein Mxe GyrA followed by a chitin-binding domain.
The ligated DNA was sequenced to confirm that there was no secondary mutation. The constructs pTXBl-NPN297 and pTXBl-NPN329 were transferred to E. coli strain ER2566 (New England Biolabs, Inc., Ipswich, MA) and grown in LB media or agar plates containing 100 μg/ml of Amp.
For purification of the truncated mutant nicking endonucleases, the following protocol was used for NPN297 and may also be used for NPN329. Single colony was inoculated to a starter culture of 100 ml of LB media containing 100 μg of Amp and grown at 37°C with 250 rpm for 12-16 hours. Ten ml of the starter culture was inoculated to 1 liter of fresh LB media containing 100 μg of Amp for 6 liters of media. The culture was incubated at 37°C with 250 rpm until OD600 reached 0.6-0.9. IPTG was added to the culture at a final concentration of 0.25 mM/L and incubation was continued for 3 hours at 37°C with 250 rpm. The cultures were centrifuged at 3,550 g at 4°C for 15 minutes. The cell pellets were stored at -2O0C. The frozen cell pellets from each liter of culture were resuspended in 15 ml of 20 mM Tris-HCI,
0.5 M NaCI, 0.1% Triton X-100, 1 mM EDTA, pH 8.5 (chitin column buffer).
The resuspended cells were lysed by sonication on ice. The lysate was centrifuged at 26,70Og for 20 min at 4°C. The supernatant of the lysate was loaded to a chitin column (20 ml bed volume) at 40C. After washing with 200 ml of chitin column buffer, the column was flushed with 40 ml of chitin column buffer with 40 mM of DTT within 10 minutes to induce cleavage of the intein. The column was incubated at 25°C for
10-16 hours. The cleaved protein was collected by washing the column with 40 ml of chitin column buffer without DTT. The eluted protein solution was diluted one-fourth using 20 mM Tris-HCI, pH 7.7 such that the sodium chloride concentration decreased to ~ 125 mM.
The diluted protein solution was loaded to a Heparin HyperD M column (BioSepra, Inc., Fremont, CA) bed volume = 30 ml) at 40C. The column was washed with 300 ml of a buffer containing 20 mM Tris-HCI, pH 7.7 and then with a linear gradient of 0 - 1 M NaCI in 20 mM Tris-HCI, pH 7.7. Fractions of 5 ml were collected and analyzed on SDS-PAGE. NPN297 was eluted in 0.6 M or higher concentration of NaCI. Fractions that contains the protein was pooled and dialyzed against 4 L of 10 mM potassium phosphate buffer, 50 mM
NaCI, 1 mM EDTA, pH 7.0 (HTP column buffer) at 4°C for 12- 16 hours. The dialyzed protein solution was loaded to a hydroxyapatite column (Bio Rad Bio-gel HTP, bed volume = 15 ml, Bio-rad Laboratories, Rockford, IL) at 2 ml/min. The column was washed with 150 ml of HTP column buffer and eluted by a linear gradient of 0 - 500 mM potassium phosophate buffer, 50 mM NaCI, 1 mM EDTA, pH 7.0. Fractions were collected for every 5 ml and analyzed using SDS-PAGE. NPN297 was found to elute at 0.25 M potassium phosphate. Fractions that contained NPN297 were pooled and dialyzed against 2 L of 40 mM Tris-HCI, 200 mM NaCI, pH 8.0 at 4°C for 12-16 hours. The dialyzed protein solution was concentrated using VivaSpin concentrator (molecular weight cut-off = 10 kDa). Equal volume of 100% glycerol was added to the concentrated protein solution. The protein preparation was stored at -200C.
DNA nicking activity of the truncation mutants
DNA nicking activity and cleavage specificity of NPN297 and NPN329 were assayed essentially the same way as for the wild-type Nt.CviPII (Example 2). The truncation mutants were found to be active with the same cleavage specificity as the wild-type Nt.CviPII. The specific activity of NPN297 and NPN329 are estimated to be 2,600 units/mg and 1,400 units/mg, respectively, compared to 9,410 U/mg of the wild- type Nt.CviPIL Although the specific activity of the truncation mutants are lower than the wild-type Nt.CviPII, the yield of the truncation mutants are much higher such that the truncation mutant generates more units of activity from the same volume of culture than the wild type.
Example 4: Isothermal amplification of DNA using Nt.CviPII and DNA polymerases with strand displacement activity
Because of the high frequency of cleavage sites and its single-stranded cleavage product, Nt.CviPII and NPN297 were used in conjunction with several DNA polymerases in isothermal random DNA amplification.
(a) Isothermal amplification of purified DNA
The following experiments were conducted with various purified DNA showing that the amplification method is generally applicable.
Two hundred ng of λ, E. coli or Thermus thermophilus genomic DNAs were incubated with 1 unit of Nt.CviPII and 16 units of Bst DNA polymerase large fragment, 8 units of Taq
DNA polymerase or 4 units of Vent DNA polymerase in ThermoPol reaction buffer at 55°C (20 mM Tris-acetate, 10 mM KCI, 10 mM (NhU)2SO4, 2 mM MgSO4, 0.1% Triton X-100, pH 8.5), or 10 units of Klenow fragment of E. coli DNA polymerase I in EcoPol buffer (10 mM Tris-HCI, 5 mM MgCI2, 7.5 mM DTT, pH 7.5) at 37°C for 30 min supplemented with 0.1 mM dNTP. The amplified DNAs were analyzed by electrophoresis on either 1.5%-2% agarose gel or 6% polyacrylamide gel containing 7 M urea in IX TBE buffer.
E. coli DNA was incubated with Nt.CviPII and various DNA polymerases and dNTPs at various temperatures for 30 min. With the Nt.CviPII, Bst DNA polymerase I large fragment generated the highest yield of DNA at 55°C. The large fragment of DNA polymerase I from Thermomicrobium roseum (U.S. patent number 5,962,296) also synthesized significant amounts of DNA while the addition of Taq DNA polymerases and Vent DNA polymerase did not result in any detectable DNA synthesis (Fig. 7A). Klenow fragment of E. coli DNA polymerase with Nt.CviPII generated a small amount of amplified DNA. Random DNA amplification can be achieved from T. thermophilus HB27 and λ DNA in the presence of Nt.CviPII/Bst DNA polymerase I large fragment but not with Bst DNA polymerase (Poll) large fragment alone (Fig. 7B). In Fig. 7C, the DNA having a Poll site in the range of < 50 to
200 nucleotides efficiently amplified. The DNA mass was amplified approximately 50-fold with 10 ng input DNA generating ~500 ng amplified small DNA fragments. The Nt.CviPII/Bst DNA pol amplified products can be further amplified by adding [N]β, [N]9 , or [N]i2 random primers together with Bst DNA pol large fragment to the amplification product by incubation at 5O0C for 60 min resulting in a second round of amplification which is expected to generate major DNA products in the range of 1 to 2 kb. Although the amplification steps described above were done at 55°C, other temperatures can be used as long as denaturation of double-stranded DNA is favored. Nt.CviPII makes frequent cuts on the DNA and produces single- stranded products or partial duplex DNA with 5' overhang (3' recessed ends) (Fig. 6). Bst DNA polymerase I large fragment then fills in at the 3' end until it reaches the end of the template. The extended DNA acted as a substrate for Nt.CviPII which, in turn, provided a new substrate for the polymerase, allowing linear amplification. The size of the amplified DNA can be increased or decreased by altering the amount (units) of Nt.CviPII in the amplification reactions.
From the collection of DNA polymerases tested, only Bst DNA polymerase I large fragment and Thermomicrobium roseum (Tro) DNA polymerase I large fragment produced significant amounts of amplified products. Klenow fragment also generated small amount of amplified DNA. These polymerases possess relatively high strand displacement activity among the polymerases tested. While not wishing to be limited by theory, strand displacement activity may be involved in removing the nicked fragment and revealing a recessive 3' end for template-dependent amplification.
It was also demonstrated that incubation of random
DNA oligonucleotides and fresh Bst DNA polymerase large fragment and dNTPs with the amplified product can result in DNA amplification. Alternatively, the amplified DNA can be purified and used as primers for direct amplification of genomic DNA through isothermal or thermocycling procedures.
Randomly amplified DNA has been used as a highly sensitive probe for arrays of DNA oligonucleotides carrying
"signature sequences" of pathogenic biological agents such as E. coli 0157: H 7 (Vo ra et al. Appl. Environ. Microbiol. 70:3047-54 (2004)). The DNA amplification method presented here does not require synthesis of primers and can generate large quantities of single-stranded DNA from a single bacterial colony within a short time frame (e.g. 10 to 30 minutes).
Unlike rolling circle amplification that can be used to generate high coverage of the genome, this DNA amplification method may not necessarily cover the entire genome. The amplified DNA can be used as a probe to detect target DNA by Southern blotting.
The procedure can be adapted for environmental or clinical samples and labels such as biotin or fluorescein can be incorporated into the amplified product by using modified deoxy-nucleotides. Development of timely, sensitive and specific detection methods to identify important pathogens is of great importance in bio-defense and public health.
(b) Isothermal amplification of DNA from a single bacterial colony Experiments were also performed to amplify DNA from a single E. coli colony using Nt.CviPII and Bst DNA polymerase I large fragment (Fig. 7D, lane 2). Single colonies of E. coli (~ 0.2 mm in diameter) were suspended in 50 ml of water, heated at 940C for 8 min, centrifuged, and 20 ml of the supernatant was used for amplification. Heating the colony at 940C for 8 min was necessary to release the DNA for optimal amplification (Fig. 7D, lane 6). Including a degenerate 4-base cutting restriction restriction endonuclease CviTI (RGΛCY) in the amplification reaction generated slightly shorter amplified DNA fragments as judged by agarose gel electrophoresis (Fig. 7B, lane 1). However, including a 4- base cutting restriction endonuclease Mspl (CΛCGG) made no difference in the size of the amplified product.
Example 5: The use of frequent nicking endonucleases such as Nt.CviPII and Nt.CviOXI to eliminate contaminant DNA from RNA samples
Nt.CviPII recognizes ACCD (D = A, T, or G), which occurs at every ~21 bp. Nt.CviQXI recognizes RΛAG (R = A or G), which occurs at every 32-64 bp. When used alone or together, the frequent nicking endonuclease(s) can degrade almost any larger DNA into very small pieces. An example of this application is to use frequent nicking endonucleases to remove genomic DNA contamination from RNA samples before reverse transcription and RT-PCR. About 500 ng rat liver total RNA was mixed with 2 μl CIT23VN (50 μM, New England Biolabs, Inc., Ipswich, MA) and 7 μl dH2O. After denaturation at 700C for five minutes, it was left on ice. A 10 μl mix containing 100 mM Tris-HCI, pH 8.3, 150 mM KCI, 6 mM MgCI2, 20 mM DTT, 8 units of M-MuLV
(New England Biolabs, Inc., Ipswich, MA), 40 units of RNase inhibitors, 100 nmole dNTP, with or without 0.5 unit wild-type Nt.CviPII or 2 units of truncated Nt.CviPII was added. After one hour incubation at 42°C, 30 μl dH2O was added to dilute the cDNA product into a 50 μl solution, from which 2 μl was used in 35-cycle PCR amplification using GAPDH-specific primers:
5' TGCMTCCTGCACCACCAACT 3' (forward primer) (SEQ ID NO:26)
5' YGCCTGCTTCACCACCTT C 3' (reverse primer) (SEQ ID NO:27)
Following RT PCR, eight μl was analysed on a 1% agarose gel (Figure 10). In the presence of M-MuLV reverse transcriptase, the RT-PCR reaction gave a specific product (lanes 2 and 4). In the absence of M-MuLV reverse transcriptase, the RT-PCR reaction also gave a specific product due to the presence of contaminating genomic DNA in the RNA sample (lane 1). When 0.5 unit of Nt.CviPII was added to the RT reaction, a significant amount of genomic DNA contaminant was removed, leading to a much weaker band when M-MuLV reverse transcriptase was not added (lane 3). When two units of Nt.CviPII was added to the RT reaction, almost all genomic DNA contaminant was degraded, leading to a non-detectable signal when M-MuLV reverse transcriptase was left out (lane 5). The results indicated that Nt.CviPII can be included in the reverse transcription step to efficiently remove genomic DNA (template) contamination. (Similar results have been obtained using Nt.CviQXI.)

Claims

1. An isolated DNA segment encoding a protein with DNA cleavage activity, wherein the encoded protein has an amino acid sequence which has at least 20% amino acid sequence identity with
SEQ ID NO 29.
2. An isolated DNA segment according to claim 1, having at least 40% DNA sequence identity with SEQ ID NO:28.
3. An isolated DNA segment according to claim 1, wherein the protein is capable of cleaving, at a specific site, a single DNA strand in a duplex.
4. An isolated DNA segment according to claim 3, wherein the specific cleavage site is selected from CCA, CCG and CCT.
5. An isolated DNA segment encoding a protein with
DNA cleavage activity, the DNA segment having a sequence characterized by at least 10 contiguous bases identical to sequences contained in SEQ ID NO:28.
6. An isolated DNA segment according to claim 5, wherein the protein is capable of cleaving at a specific cleavage site on a single DNA strand in a duplex.
7. An isolated DNA segment according to claim 6, wherein the specific cleavage site is selected from CCA, CCG and CCT.
8. An isolated DNA segment encoding a protein with
DNA methylase activity, wherein the protein has at least 47% sequence identity with SEQ ID NO:31.
9. An isolated DNA segment according to claim 8, wherein the DNA segment has a DNA sequence with at least
53% sequence identity with SEQ ID NO:30.
10. A recombinant nicking endonuclease, comprising an amino acid sequence with at least 25% sequence identity with SEQ ID NO:29.
11. A recombinant DNA methylase, comprising an amino acid sequence with at least 47% sequence identity with SEQ ID NO:31.
12. A recombinant nicking endonuclease according to claim 10, wherein the endonuclease is a mutant having a sequence truncation at the C-terminal end compared with a native nicking endonuclease.
13. A recombinant nicking endonuclease according to claim 12, wherein 51 amino acid residues at the C-terminus have been removed.
14. A recombinant nicking endonuclease according to claim 12, wherein the 19 amino acid residues at the C- terminus have been removed.
15. A recombinant nicking endonuclease according to claim 12, having a cleavage specificity selected from CCA, CCG and CCT.
16. A recombinant nicking endonuclease according to claim 12, having a substantially similar cleavage activity to the native endonuclease.
17. A vector comprising a segment of DNA, the DNA further comprising at least 10 contiguous bases identical to sequences contained in SEQ ID NO:28.
18. A host cell comprising the vector of claim 17.
19. A method for amplification of DNA, comprising : (a) incubating the DNA with a DNA polymerase capable of strand displacement and a recombinant nicking endonuclease according to claims 10,12, 13 or 14; and (b) obtaining amplified DNA.
20. A method according to claim 19, wherein the amplification is isothermal.
21. A method according to claim 19, further comprising: (c) subjecting the amplified DNA from (b) to an additional amplification step in the presence of random primers and a strand displacement polymerase to enhance the yield of the amplification.
22. A method according to claims 19 or 21, wherein the DNA polymerase is selected from Bst polymerase,
Thermomicrobium roseum pol I and E. coli DNA polymerase large (Klenow) fragment.
23. A method according to claims 19, 21 or 22, wherein the recombinant nicking endonuclease is Nt.CviPII.
24. A method according to claims 19, 21 or 22, wherein the DNA is obtained from a single bacterial colony.
25. A method for eliminating genomic DNA from a sample of biological material, comprising :
(a) adding Nt.CviPII nicking endonuclease or mutant thereof to the sample of biological material; and
(b) allowing the nicking endonuclease or mutant thereof to cleave the genomic DNA so as to eliminate the genomic
DNA from the sample of biological material.
26. A method for cloning a toxic nicking endonuclease; comprising: removing a C-terminal sequence from the DNA encoding the toxic nicking endonuclease; and cloning the truncated gene in a suitable host cell.
27. A method according to claim 25, wherein the host cell is E. coli.
28. A method according to claim 25, wherein the toxic nicking endonuclease is derived from a Chlorella virus.
PCT/US2005/037607 2004-05-25 2005-10-21 Recombinant dna nicking endonuclease and uses thereof WO2006047183A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/666,148 US20080268507A1 (en) 2004-05-25 2005-10-21 Recombinant Dna Nicking Endonuclease and Uses Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62093904P 2004-10-21 2004-10-21
US60/620,939 2004-10-21

Publications (2)

Publication Number Publication Date
WO2006047183A2 true WO2006047183A2 (en) 2006-05-04
WO2006047183A3 WO2006047183A3 (en) 2006-08-03

Family

ID=36228241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/037607 WO2006047183A2 (en) 2004-05-25 2005-10-21 Recombinant dna nicking endonuclease and uses thereof

Country Status (2)

Country Link
US (1) US20080268507A1 (en)
WO (1) WO2006047183A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045141A1 (en) 2016-09-02 2018-03-08 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
US10246705B2 (en) * 2011-02-10 2019-04-02 Ilumina, Inc. Linking sequence reads using paired code tags
CN109763172A (en) * 2017-11-09 2019-05-17 深圳华大生命科学研究院 A kind of mutant nucleic acid library construction method and obtained mutant nucleic acid library
WO2019099081A1 (en) 2017-11-16 2019-05-23 New England Biolabs, Inc. Mapping the location, type and strand of damaged and/or mismatched nucleotides in double-stranded dna
US10457936B2 (en) 2011-02-02 2019-10-29 University Of Washington Through Its Center For Commercialization Massively parallel contiguity mapping
US10557133B2 (en) 2013-03-13 2020-02-11 Illumina, Inc. Methods and compositions for nucleic acid sequencing
US10988760B2 (en) 2013-01-09 2021-04-27 Illumina Cambridge Limited Sample preparation on a solid support
US11149310B2 (en) 2013-12-20 2021-10-19 Illumina, Inc. Preserving genomic connectivity information in fragmented genomic DNA samples
US11492667B2 (en) 2020-06-12 2022-11-08 New England Biolabs, Inc. Compositions and methods for detecting molecular targets on chromosomal DNA
WO2023234419A1 (en) * 2022-05-30 2023-12-07 国立大学法人九州大学 Dna methyltransferase
US11873480B2 (en) 2014-10-17 2024-01-16 Illumina Cambridge Limited Contiguity preserving transposition

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
JP6367196B2 (en) 2012-08-14 2018-08-01 テンエックス・ジェノミクス・インコーポレイテッド Microcapsule composition and method
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
EP3567116A1 (en) 2012-12-14 2019-11-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9644204B2 (en) 2013-02-08 2017-05-09 10X Genomics, Inc. Partitioning and processing of analytes and other species
KR102531677B1 (en) 2014-06-26 2023-05-10 10엑스 제노믹스, 인크. Methods of analyzing nucleic acids from individual cells or cell populations
EP3244992B1 (en) * 2015-01-12 2023-03-08 10X Genomics, Inc. Processes for barcoding nucleic acids
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
EP4286516A3 (en) 2015-02-24 2024-03-06 10X Genomics, Inc. Partition processing methods and systems
JP7305812B2 (en) * 2016-07-19 2023-07-10 株式会社バイオダイナミクス研究所 Method for preparing long single-stranded DNA
WO2018140966A1 (en) 2017-01-30 2018-08-02 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
CN109526228B (en) 2017-05-26 2022-11-25 10X基因组学有限公司 Single cell analysis of transposase accessible chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
EP3625361A1 (en) 2017-11-15 2020-03-25 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11021701B2 (en) 2017-11-22 2021-06-01 New England Biolabs, Inc. Method for fragmenting DNA by nick translation
WO2022187334A1 (en) * 2021-03-03 2022-09-09 Yale University High-yield probe library construction
WO2022261281A1 (en) 2021-06-09 2022-12-15 New England Biolabs, Inc. Target initiation and amplification of long dna with nuclease and replisome enzymes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021663A1 (en) * 1993-03-24 1994-09-29 Molecular Biology Resources, Inc. Dinucleotide restriction endonuclease preparations and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660475B2 (en) * 2000-12-15 2003-12-09 New England Biolabs, Inc. Use of site-specific nicking endonucleases to create single-stranded regions and applications thereof
EP1501950A4 (en) * 2002-04-12 2006-03-15 New England Biolabs Inc Methods and compositions for dna manipulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021663A1 (en) * 1993-03-24 1994-09-29 Molecular Biology Resources, Inc. Dinucleotide restriction endonuclease preparations and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ [Online] MEAD ET AL: 'Di: nucleotide restriction endonuclease CviJI and DNA- used in DNA fragmentation and primer production.' Database accession no. (AAR63443) & WO 94 21663 A1 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299730B2 (en) 2011-02-02 2022-04-12 University Of Washington Through Its Center For Commercialization Massively parallel contiguity mapping
US11999951B2 (en) 2011-02-02 2024-06-04 University Of Washington Through Its Center For Commercialization Massively parallel contiguity mapping
US10457936B2 (en) 2011-02-02 2019-10-29 University Of Washington Through Its Center For Commercialization Massively parallel contiguity mapping
US10246705B2 (en) * 2011-02-10 2019-04-02 Ilumina, Inc. Linking sequence reads using paired code tags
US11993772B2 (en) 2011-02-10 2024-05-28 Illumina, Inc. Linking sequence reads using paired code tags
US11970695B2 (en) 2013-01-09 2024-04-30 Illumina Cambridge Limited Sample preparation on a solid support
US10988760B2 (en) 2013-01-09 2021-04-27 Illumina Cambridge Limited Sample preparation on a solid support
US10557133B2 (en) 2013-03-13 2020-02-11 Illumina, Inc. Methods and compositions for nucleic acid sequencing
US11319534B2 (en) 2013-03-13 2022-05-03 Illumina, Inc. Methods and compositions for nucleic acid sequencing
US11149310B2 (en) 2013-12-20 2021-10-19 Illumina, Inc. Preserving genomic connectivity information in fragmented genomic DNA samples
US11873480B2 (en) 2014-10-17 2024-01-16 Illumina Cambridge Limited Contiguity preserving transposition
EP4219746A2 (en) 2016-09-02 2023-08-02 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
EP3885448A1 (en) 2016-09-02 2021-09-29 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
US11840741B2 (en) 2016-09-02 2023-12-12 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
US11198910B2 (en) 2016-09-02 2021-12-14 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
WO2018045141A1 (en) 2016-09-02 2018-03-08 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
CN109763172A (en) * 2017-11-09 2019-05-17 深圳华大生命科学研究院 A kind of mutant nucleic acid library construction method and obtained mutant nucleic acid library
US11713484B2 (en) 2017-11-16 2023-08-01 New England Biolabs, Inc. Mapping the location, type and strand of damaged and/or mismatched nucleotides in double-stranded DNA
EP4276197A2 (en) 2017-11-16 2023-11-15 New England Biolabs, Inc. Mapping the location, type and strand of damaged nucleotides in double-stranded dna
WO2019099081A1 (en) 2017-11-16 2019-05-23 New England Biolabs, Inc. Mapping the location, type and strand of damaged and/or mismatched nucleotides in double-stranded dna
US11492667B2 (en) 2020-06-12 2022-11-08 New England Biolabs, Inc. Compositions and methods for detecting molecular targets on chromosomal DNA
WO2023234419A1 (en) * 2022-05-30 2023-12-07 国立大学法人九州大学 Dna methyltransferase

Also Published As

Publication number Publication date
US20080268507A1 (en) 2008-10-30
WO2006047183A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
US20080268507A1 (en) Recombinant Dna Nicking Endonuclease and Uses Thereof
JP4817587B2 (en) N. Methods for cloning and production of BstNBI cleavage endonuclease and use of the cleavage endonuclease in single strand displacement amplification
KR100882711B1 (en) Uracil-DNA glycosylase of Psychrobacter sp. HJ147 and use thereof
Drozdz et al. Novel non-specific DNA adenine methyltransferases
US9650618B2 (en) Endonucleases
Chan et al. Cloning of CviPII nicking and modification system from chlorella virus NYs-1 and application of Nt. CviPII in random DNA amplification
JP2003519490A (en) Talauracil-DNA glycosylase, gene encoding it, recombinant DNA containing the gene or functional part thereof, method for preparing the protein, and use of the protein or functional part thereof in PCR tracking or regulation
LT5263B (en) A method for engeneering strand-specific nicking endonucleases from restriction endonucleazes
Česnavičienė et al. Characterization of AloI, a restriction-modification system of a new type
US6245545B1 (en) Method for cloning and producing the SwaI restriction endonuclease
KR100787995B1 (en) - Novel Uracil-DNA Glycosylase and Use Thereof
Chan et al. Cloning of Nt. CviQII nicking endonuclease and its cognate methyltransferase: M. CviQII methylates AG sequences
Jurenaite-Urbanaviciene et al. Characterization of bse MII, a new type IV restriction–modification system, which recognizes the pentanucleotide sequence 5′-CTCAG (N) 10/8↓
Kaplan et al. Recombinant production of Thermus aquaticus single-strand binding protein for usage as PCR enhancer
Krefft et al. Two-stage gene assembly/cloning of a member of the TspDTI subfamily of bifunctional restriction endonucleases, TthHB27I
US20040209257A1 (en) Method for cloning and expression of AcuI restriction endonuclease and AcuI methylase in E. coli
Rao et al. Methanococcus jannaschii flap endonuclease: expression, purification, and substrate requirements
US7186538B2 (en) Type II restriction endonuclease, CstMI, obtainable from Corynebacterium striatum M82B and a process for producing the same
US5516678A (en) Method for producing the SSPI restriction endonuclease and methylase
Szilák et al. Purification and biochemical characterization of the Ecal DNA methyltransferase
US6403354B1 (en) Method for cloning and expression of BstYI restriction endonuclease and BstYI methylase in E. coli and purification of BstYI and M.BstYI enzymes
Azarinskas et al. Hin4II, a new prototype restriction endonuclease from Haemophilus influenzae RFL4: discovery, cloning and expression in Escherichia coli
US6764843B2 (en) Method of cloning and expression of BsmBI restriction endonuclease and BsmBI methylase in E. coli and purification of BsmBI endonuclease
US6586220B1 (en) Method for cloning and expression of BsaWI restriction endonuclease and BsaWI methylase in E. coli
US20050003420A1 (en) Recycled mutagenesis of restriction endonuclease toward enhanced catalytic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815213

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11666148

Country of ref document: US